Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/8931
Title: A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours
Authors: Araújo, Elaine Bortoleti de
Pujatti, Priscilla Brunelli
Caldeira Filho, Jose de Souza
Colturato, Maria Tereza
Muramoto, Emiko
Nagamati, Lúcio Takeshi
Couto, Renata Martinussi
Mengatti, Jair
Silva, Christiano Pereira
Keywords: Somatostatina
Somatostatin
Tumores Neuroendócrinos
Neuroendocrine Tumors
Tumores Neuroendocrinos
Terapia Molecular Dirigida
Terapia de Alvo Molecular
Molecular Targeted Therapy
Issue Date: 2009
Publisher: Applied Radiation and Isotopes
Citation: ARAÚJO, Elaine Bortoleti de et al. A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours. Applied Radiation and Isotopes, v. 67, p. 227–233, 2009.
Abstract: This work analysed the influence of the chelating group and radioligand on somatostatin analogues in vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled analogue with similar blood kinetics and biodistribution to 177Lu-DOTATATE and with lower abdominal uptake than 131I-TATE. In addition, 131I-DOTATATE showed significative tumour uptake, despite not so persistent after 24 h. 131I-DOTATATE can represent a cost-effective alternative to lutetium labeled peptide for neuroendocrine tumours therapy.
Description: p. 227–233.: il p&b. e color.
URI: http://sr-vmlxaph03:8080/jspui/handle/123456789/8931
Appears in Collections:Artigos de Periódicos da área de Farmácia



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.